Everything below concerns lipogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-03. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The mould needs air to grow, so cultivation required a container with a large surface area. Initially, glass bottles laid on their sides were used. Most laboratory containers did not provide a large, flat area, and so were an uneconomical use of incubator space. The bedpan was found to be practical, and was the basis for specially-made ceramic containers fabricated by J. Macintyre and Company in Burslem. These containers were rectangular in shape and could be stacked to save space. The MRC agreed to Florey's request for £300 (equivalent to £15,000 in 2025) and £2 each per week (equivalent to £97 in 2025) for two women factory hands. In 1943 Florey asked for their wages to be increased to £2 10s each per week (equivalent to £99 in 2025). Heatley collected the first 174 of an order for 500 vessels on 22 December 1940, and they were seeded with spores three days later. Efforts were made to coax the mould into producing more penicillin. Heatley tried adding various substances to the medium, including sugars, salts, malts, alcohol and even marmite, without success. At the suggestion of Paul Fildes, he tried adding brewing yeast. This did not improve the yield either, but it did cut the incubation time by a third. The team also discovered that if the penicillin-bearing fluid was removed and replaced by fresh fluid, a second batch of penicillin could be prepared, but this practice was discontinued after eighteen months due to the danger of contamination. The mould had to be grown under sterile conditions.
=== 2010 census === As of the census of 2010, there were 4,025 people, 1,549 households, and 1,049 families living in the city. The population density was 1,507.5 inhabitants per square mile (582.0/km2). There were 1,641 housing units at an average density of 614.6 units per square mile (237.3 units/km2). The racial makeup of the city was 94.2% White, 0.2% African American, 0.2% Native American, 0.2% Asian, 0.1% Pacific Islander, 3.9% from other races, and 1.0% from two or more races. Hispanic or Latino of any race were 7.1% of the population. There were 1,549 households, of which 36.6% had children under the age of 18 living with them, 53.6% were married couples living together, 10.1% had a female householder with no husband present, 4.0% had a male householder with no wife present, and 32.3% were non-families. 27.8% of all households were made up of individuals, and 16.4% had someone living alone who was 65 years of age or older. The average household size was 2.54 and the average family size was 3.11. The median age in the city was 36.7 years. 27.7% of residents were under the age of 18; 6.5% were between the ages of 18 and 24; 26.4% were from 25 to 44; 20.4% were from 45 to 64; and 19% were 65 years of age or older. The gender makeup of the city was 48.3% male and 51.7% female. Ancestry breakdown of residents is German (67.6%), American (5.9%), Swedish (4.0%), Irish (2.4%), Norwegian (1.7%), English (1.2%).
There he was reunited with Mark Thompson, who was head coach at Geelong during Robinson's time. In February 2013, Essendon announced that they had reported themselves to Australian Sports Anti-Doping Authority (ASADA) to investigate the possible use of banned substances. Robinson, as the club's fitness boss, was stood down from his position pending the results of the enquiry. His link to Stephen Dank, a controversial sports scientist who was introduced to Essendon by Robinson, was investigated by the AFL. Hinting at further revelations, former ASADA head Richard Ings said "this is not a black day in Australian sport, this is the blackest day." Following the uproar, a chorus of accredited individuals leap to the defence of the newly embattled fitness coach. Central among these was three-time Geelong premiership player and Norm Smith medalist Paul Chapman. Chapman, shocked at the claims involving Robinson, was highly supportive of the man to whom he attributed much of his own personal success. Speaking highly of his former mentor, Chapman said Robinson was a true "family man" and suggested he had been shamed "simply by association". Denouncing the press gallery, Chapman maintained that a trial by media had left Robinson guilty until proven innocent. Geelong captain Joel Selwood expressed similar admiration for the man, describing Robinson as a "legend of a bloke", while football chief Neil Balme and current Gold Coast captain Gary Ablett also lent their support.
Pharmacy automation involves the mechanical processes of handling and distributing medications. Any pharmacy task may be involved, including counting small objects (e.g., tablets, capsules); measuring and mixing powders and liquids for compounding; tracking and updating customer information in databases (e.g., personally identifiable information (PII), medical history, drug interaction risk detection); and inventory management.
Mitragotri has invented many novel drug delivery technologies, especially in the fields of transdermal, oral and targeted systems. He invented techniques to deliver drugs transdermally using low-frequency ultrasound, pulsed microjet injector, high throughput skin experimentation, skin penetrating peptides and ionic liquids. He also invented intestinal patches and ionic liquids for oral delivery of proteins. Mitragotri also pioneered nanoparticle-enabled cell therapies which use drug-loaded nanoparticles that hitch a ride on red blood cells, monocytes and other circulatory cells for tissue-specific delivery. Mitragotri's technologies are used to develop next generation therapies against diabetes, cancer, psoriasis, hemorrhage, trauma and infections. Mitragotri has published over 400 research publications and is an inventor on over 300 patents/applications. His publications are cited over 81000 times with an h-index of 140. Mitragotri is a member of the US National Academy of Medicine and the US National Academy of Inventors. He is also a member of the US National Academy of Engineering since 2015 for the development, clinical translation, and commercialization of transdermal drug delivery systems. He is also an elected member of The World Academy of Science , American Academy of Arts & Sciences and Indian National Academy of Engineering. He is a co-founder of several companies that are developing products based on his inventions. He received his PhD in chemical engineering at MIT and BS in chemical engineering from the Institute of Chemical Technology.
Sources: en.wikipedia.org
The attraction between the charged metal and water ions will rapidly increase the surface area, causing an exponential increase of ionisation. When the repulsive forces within the liquid metal surface exceeds the forces of the surface tension, it vigorously explodes. The hydroxides themselves are the most basic hydroxides known, reacting with acids to give salts and with alcohols to give oligomeric alkoxides. They easily react with carbon dioxide to form carbonates or bicarbonates, or with hydrogen sulfide to form sulfides or bisulfides, and may be used to separate thiols from petroleum. They react with amphoteric oxides: for example, the oxides of aluminium, zinc, tin, and lead react with the alkali metal hydroxides to give aluminates, zincates, stannates, and plumbates. Silicon dioxide is acidic, and thus the alkali metal hydroxides can also attack silicate glass.
Bohemian-style absinth is also referred to as Czech-style absinthe, anise-free absinthe, or just "absinth" (without the "e"), and is best described as a wormwood bitters. It is produced mainly in the Czech Republic, from which it gets its designation as Bohemian or Czech, although not all absinthes from the Czech Republic are Bohemian-style. Bohemian-style absinth typically contains little or none of the anise, fennel, and other herbal flavours associated with traditional absinthe, and thus bears very little resemblance to the absinthes made popular in the 19th century. Typical Bohemian-style absinth has only two similarities with its authentic, traditional counterpart: it contains wormwood and has a high alcohol content. The Czechs are credited with inventing the fire ritual in the 1990s, possibly because Bohemian-style absinth does not louche, which renders the traditional French preparation method useless. As such, this type of absinthe and the fire ritual associated with it are entirely modern fabrications and have little to no relationship with the historical absinthe tradition.
Skp, Cullin, F-box containing complex (or SCF complex) is a multi-protein E3 ubiquitin ligase complex that catalyzes the ubiquitination of proteins destined for 26S proteasomal degradation. Along with the anaphase-promoting complex, SCF has important roles in the ubiquitination of proteins involved in the cell cycle. The SCF complex also marks various other cellular proteins for destruction.
=== Amphetamines === Amphetamines are the largest group of stimulants. Amphetamine was first used in the 1930s as a drug to treat various medical conditions such as narcolepsy and depression. However, during World War II, amphetamine was given to soldiers to keep them awake and alert. Soon, it leads to athletes abusing it to gain an advance. Usage of stimulants, such as amphetamine, can lead to death. In 1960, Danish cyclist Kurt Enemar Jensen died from amphetamine use during the Summer Olympics, and British cyclist Tommy Simpson died during the 1967 Tour de France with alcohol and amphetamines in his system. Amphetamines manipulate the levels of certain neurotransmitters in the central nervous system (CNS) and the peripheral nervous system (PNS).
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.